Adalimumab biosimilar Fresenius Kabi
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Adalimumab biosimilar Fresenius Kabi, covering 2024-06-12 to 2024-06-12. Get the full timeline:
Most recent: Clinical Trial Update: SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases